Literature DB >> 24825115

Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.

Mai T Pho1, Benjamin P Linas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24825115      PMCID： PMC4096113          DOI： 10.1002/hep.27220

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.298


× No keyword cloud information.
  7 in total

Review 1.  Interpretation of cost-effectiveness analyses.

Authors:  D K Owens
Journal:  J Gen Intern Med       Date:  1998-10       Impact factor: 5.128

Review 2.  The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection.

Authors:  Daniel A Ollendorf; Jeffrey A Tice; Steven D Pearson
Journal:  JAMA Intern Med       Date:  2014-07       Impact factor: 21.873

3.  Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.

Authors:  Liesl M Hagan; Mark S Sulkowski; Raymond F Schinazi
Journal:  Hepatology       Date:  2014-05-14       Impact factor: 17.425

4.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

Review 5.  Hepatitis C virus therapy in the direct acting antiviral era.

Authors:  Mitchell L Shiffman
Journal:  Curr Opin Gastroenterol       Date:  2014-05       Impact factor: 3.287

6.  Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.

Authors:  Christophe Hézode; Helene Fontaine; Celine Dorival; Fabien Zoulim; Dominique Larrey; Valerie Canva; Victor De Ledinghen; Thierry Poynard; Didier Samuel; Marc Bourliere; Laurent Alric; Jean-Jacques Raabe; Jean-Pierre Zarski; Patrick Marcellin; Ghassan Riachi; Pierre-Henri Bernard; Veronique Loustaud-Ratti; Olivier Chazouilleres; Armand Abergel; Dominique Guyader; Sophie Metivier; Albert Tran; Vincent Di Martino; Xavier Causse; Thong Dao; Damien Lucidarme; Isabelle Portal; Patrice Cacoub; Jerome Gournay; Veronique Grando-Lemaire; Patrick Hillon; Pierre Attali; Thierry Fontanges; Isabelle Rosa; Ventzislava Petrov-Sanchez; Yoann Barthe; Jean-Michel Pawlotsky; Stanislas Pol; Fabrice Carrat; Jean-Pierre Bronowicki
Journal:  Gastroenterology       Date:  2014-04-03       Impact factor: 22.682

7.  Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.

Authors:  Andrew Hill; Saye Khoo; Joe Fortunak; Bryony Simmons; Nathan Ford
Journal:  Clin Infect Dis       Date:  2014-01-06       Impact factor: 9.079
  7 in total
  4 in total

1.  Barriers to Treatment Among New York City Residents with Chronic Hepatitis C Virus Infection, 2014.

Authors:  Andrea King; Katherine Bornschlegel; Nirah Johnson; Eric Rude; Fabienne Laraque
Journal:  Public Health Rep       Date:  2016 May-Jun       Impact factor: 2.792

2.  Clinical impact of treatment timing for chronic hepatitis C infection: a decision model.

Authors:  M T Pho; D M Jensen; D O Meltzer; A Y Kim; B P Linas
Journal:  J Viral Hepat       Date:  2015-08       Impact factor: 3.517

3.  Duplex High-Resolution Melting Assay for the Simultaneous Genotyping of IL28B rs12979860 and PNPLA3 rs738409 Polymorphisms in Chronic Hepatitis C Patients.

Authors:  Elena L Enache; Anca Sin; Ligia Bancu; Christophe Ramière; Olivier Diaz; Patrice André; Liviu S Enache
Journal:  Int J Mol Sci       Date:  2015-09-14       Impact factor: 5.923

Review 4.  The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis.

Authors:  Christina Greenaway; Ann Thu Ma; Lorie A Kloda; Marina Klein; Sonya Cnossen; Guido Schwarzer; Ian Shrier
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.